Albany, NY, April 6, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research "Active Pharmaceutical Ingredients (API) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020," the global active pharmaceutical ingredients market was valued at USD 119.7 billion in 2013 and is anticipated to reach USD 185.9 billion by 2020, expanding at a CAGR of 6.5% during the forecast period from 2014 to 2020.
Browse Full Market Research of Active Pharmaceutical Ingredients (API) Market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
According to the World Health Organization (WHO), in 2012, cancer was among the leading causes of morbidity and mortality worldwide, with approximately 14 million newly diagnosed cases and 8.2 million cancer-related deaths. Therefore, the oncology segment is expected to be fastest growing segment in the global API market. Moreover, most of the drugs in this segment contain High Potency Active Pharmaceutical Ingredients (HPAPIs) which itself is a rapidly growing segment in the global API market. The market growth of this segment will be particularly higher than other segments owing to loss of patent protection for blockbuster drugs such as Herceptin (Roche), Arimidex (AstraZeneca), Xeloda (Roche), Abraxane (Celgene), Temodar (Merck & Co.) and Vidaza (Celgene) between 2010 and 2014.
Browse Press Release of Active Pharmaceutical Ingredients Market: http://www.transparencymarketresearch.com/pressrelease/active-pharmaceutical-ingredients.htm
The global active pharmaceutical ingredients market is segmented on the basis of therapeutic area into non-steroidal anti-inflammatory drugs (NSAIDS), oncology drugs, anti-diabetic drugs, cardiovascular drugs, central nervous system drugs, musculoskeletal drugs, and others. The overall API market is expected to witness substantial growth during the forecast period from 2014 to 2020, wherein oncology and central nervous system drugs segments would play a vital role. These segments are expected to grow at the highest CAGR during the forecast period from 2014 to 2020. Cardiovascular drugs accounted for the largest market revenue share in 2013 due to the rising prevalence of cardiovascular diseases, sedentary lifestyle, and aging population. Bestselling products losing market exclusivity has been a common trend in all market segments, thus creating opportunities for generic products. This in turn increases the demand for APIs in particular therapeutics segments.
Get Sample Report Copy OR For further inquiries, click here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690
Currently, biological drugs are gaining importance in the treatment of chronic diseases such as cancer and diabetes. These drugs are costlier due to challenging set of manufacturing requirements and difficult replication as against chemical APIs. Advancements in the production technology have enabled production of biosimilars that are not exact copies of innovator drugs, but highly comparable in terms of safety and efficacy. Europe has been the frontrunner in approving biosimilars, and the WHO has also set guidelines on similar lines of those set by the European Union. Regulatory pathways in the biosimilars space in different nations are evolving and this implies a great market opportunity ahead for the biopharmaceutical companies. Approval of the first biosimilar in the U.S. for filgrastim (2015) indicates opening up of the highly regulated U.S. market, which would further push the overall API market growth.
Major players competing in this market include Boehringer Ingelheim Group, Cambrex Corporation, Dr. Reddy's Laboratories, Ltd., BASF SE, Hospira, Inc., Lonza Group, Mylan, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Actavis plc, and Wuxi Apptec.
Other Reports By Transparency Market Research :
- Hospital Pharmaceuticals Market: http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html
- Healthcare CMO Market: http://www.transparencymarketresearch.com/healthcare-cmo-market.html
The global active pharmaceutical ingredients market is segmented as follows:
Active Pharmaceutical Ingredients Market, by Type of Manufacturing
- Captive or In-house API manufacturing
- API contract manufacturing
Active Pharmaceutical Ingredients Market, by Type of API
- Synthetic Chemical API
- Biological API
Active Pharmaceutical Ingredients Market, by Type of Drug
- Branded or Innovative Prescription Drugs
- Generic Prescription Drugs
- Over-the-counter Drugs
Active Pharmaceutical Ingredients Market, by Therapeutic Area
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Oncology Drugs
- Anti-diabetic Drugs
- Cardiovascular Drugs
- Central Nervous System Drugs
- Musculoskeletal Drugs
- Other Drugs (antibacterial, antiviral, antifungal, etc.)
Active Pharmaceutical Ingredients Market, by Geography
- North America
- Europe
- Asia Pacific
- Rest of the World (RoW)
Browse All Pharmaceutical Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us :
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.